Figure 1 | British Journal of Cancer

Figure 1

From: Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models

Figure 1

Growth inhibition of human tumour xenografts in mice treated with VEGFR2 kinase inhibitors, GW654652, GW612286, or GW695612. Animals with 100–200 mm3 tumour volume were randomly assigned to either vehicle or treatment group (n=8 mice group−1) as described in Materials and Methods. All compounds were administered orally at 30 mg kg−1 once daily, except GW695612 (30 mg kg−1, twice day−1). Data represent tumour growth inhibition (mean±s.e.m.) in drug-treated animals compared to vehicle-treated mice after 21 days of dosing.

Back to article page